Table 3.
Details of the sensitivity analyses.
| Sensitivity analysis | GLP-1 RA (n) | SGLT-2 inhibitor (n) | Comparison | RR | 95% CI | I2 (%) | P-value |
|---|---|---|---|---|---|---|---|
| For obese participants with T2DM | |||||||
| Without CREDENCE (limiting primary outcomes) | 30,760 | 21,873 | GLP-1 RA vs. placebo | 0.88 | 0.82–0.95 | 26 | 0.20 |
| SGLT-2 inhibitor vs. placebo | 0.94 | 0.85–1.03 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.94 | 0.83–1.06 | |||||
| Without REWIND | 26,177 | 24,239 | GLP-1 RA vs. placebo | 0.89 | 0.81–0.98 | 37 | 0.11 |
| SGLT-2 inhibitor vs. placebo | 0.91 | 0.83–1.00 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.98 | 0.86–1.12 | |||||
| Liraglutide and subcutaneous semaglutide | 3,969 | 24,239 | GLP-1 RA vs. placebo | 0.83 | 0.70–0.99 | 42 | 0.13 |
| SGLT-2 inhibitor vs. placebo | 0.91 | 0.82–1.01 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.91 | 0.75–1.11 | |||||
| Daily GLP-1 RA | 9,028 | 24,239 | GLP-1 RA vs. placebo | 0.93 | 0.78–1.10 | 55 | 0.038 |
| SGLT-2 inhibitor vs. placebo | 0.91 | 0.81–1.02 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 1.02 | 0.83–1.25 | |||||
| Weekly GLP-1 RA | 21,732 | 24,239 | GLP-1 RA vs. placebo | 0.87 | 0.78–0.95 | 30 | 0.19 |
| SGLT-2 inhibitor vs. placebo | 0.91 | 0.84–1.00 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.95 | 0.83–1.08 | |||||
| For non-obese participants with T2DM | |||||||
| Without CREDENCE (limiting primary outcomes) | 21,992 | 15,591 | GLP-1 RA vs. placebo | 0.88 | 0.79–0.98 | 50 | 0.037 |
| SGLT-2 inhibitor vs. placebo | 0.91 | 0.80–1.04 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.97 | 0.81–1.15 | |||||
| Without REWIND | 16,675 | 17,617 | GLP-1 RA vs. placebo | 0.86 | 0.76–0.98 | 49 | 0.040 |
| SGLT-2 inhibitor vs. placebo | 0.90 | 0.79–1.02 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.93 | 0.75–1.16 | |||||
| Liraglutide and subcutaneous semaglutide | 2,339 | 17,617 | GLP-1 RA vs. placebo | 0.84 | 0.66–1.07 | 56 | 0.047 |
| SGLT-2 inhibitor vs. placebo | 0.90 | 0.78–1.03 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.94 | 0.71–1.24 | |||||
| Daily GLP-1 RA | 6,519 | 17,617 | GLP-1 RA vs. placebo | 0.94 | 0.81–1.09 | 29 | 0.21 |
| SGLT-2 inhibitor vs. placebo | 0.90 | 0.81–1.01 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 1.04 | 0.87–1.25 | |||||
| Weekly GLP-1 RA | 15,473 | 17,617 | GLP-1 RA vs. placebo | 0.85 | 0.73–0.98 | 53 | 0.039 |
| SGLT-2 inhibitor vs. placebo | 0.90 | 0.79–1.03 | |||||
| GLP-1 RA vs. SGLT-2 inhibitor | 0.94 | 0.77–1.14 | |||||
SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; RR, relative risk; CI, confidence interval.